Product Description
JNJ-64232025 is a monoclonal antibody targeting CD154 (also known as CD40 ligand), which is being developed for T cell-mediated autoimmune disorders.
Mechanisms of Action: CD40 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous, Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: Eastern America
Company CEO: Joaquin Duato
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03550950 |
CR108448 | P1 |
Completed |
Healthy Volunteers |
2019-02-05 |
12% |
2019-03-22 |
Patient Enrollment|Primary Completion Date|Study Completion Date |
Recent News Events
Date |
Type |
Title |
|---|